This document provides an overview of Pfizer's research and development strategies and opportunities for growth through strategic alliances. It discusses Pfizer's global R&D operations and pipeline, challenges in the pharmaceutical industry around shrinking market exclusivity and high drug development attrition rates. It also outlines Pfizer's approaches to alliances like pursuing opportunities aggressively, taking a standard approach, or prioritizing areas of social need. The document emphasizes Pfizer's leadership in biopharmaceutical strategic alliances and investments in external innovation.
The document discusses DTECTM, a service that analyzes healthcare claims data to identify gaps in quality of care for patient populations with cardiovascular diseases. It produces reports that assess baseline performance, identify barriers, target individuals for intervention, and reassess performance. Examples show how DTECTM was used by health plans to measure quality indicators, identify members for programs, and document trends over time. The document suggests DTECTM could help Quality Improvement Organizations and Medicare Part D by leveraging claims data to provide insights into care quality and support clinical decision making.
This document provides an overview of Pfizer's research and development strategies and opportunities for growth through strategic alliances. It discusses Pfizer's global R&D operations and pipeline, challenges in the pharmaceutical industry around shrinking market exclusivity and high drug development attrition rates. It also outlines Pfizer's approaches to alliances like pursuing opportunities aggressively, taking a standard approach, or prioritizing areas of social need. The document emphasizes Pfizer's leadership in biopharmaceutical strategic alliances and investments in external innovation.
The document discusses DTECTM, a service that analyzes healthcare claims data to identify gaps in quality of care for patient populations with cardiovascular diseases. It produces reports that assess baseline performance, identify barriers, target individuals for intervention, and reassess performance. Examples show how DTECTM was used by health plans to measure quality indicators, identify members for programs, and document trends over time. The document suggests DTECTM could help Quality Improvement Organizations and Medicare Part D by leveraging claims data to provide insights into care quality and support clinical decision making.
The document discusses the globalization of innovation in the pharmaceutical industry. It covers trends showing the rise of innovation capabilities in other countries. Key opportunities for pharmaceutical companies include accessing skilled workforces and scientific capabilities around the world. Drivers enabling global innovation are increasing intellectual property protections, investments in research, and partnerships across countries. Challenges include threats to intellectual property from changes in patent laws and compulsory licensing of drugs. The industry must navigate regulation and litigation while bringing new medicines to patients globally.
Клуб "Историческа лаборатория", ПГ по икономика-Шумен представи историята на училището на Патронния празник - 6 декември 2013 г. Поздравления за Мария, Йоанна, Джанел и Станислава от 9 а клас!
Modeling and simulation has impacted drug development decision-making by allowing evaluation of different study designs, doses, and regimens using computer simulations. For a potential Alzheimer's drug, trial simulations were used to compare different study designs and select a 4x4 Latin square design with 4-week treatment periods. This design was predicted to have the best power to detect drug effects and correctly characterize the dose-response relationship. In another example, population PK/PD modeling of gabapentin clinical trial data supported the drug's efficacy in neuropathic pain at 1800 mg and 2400 mg daily doses.
Безплатни консултации и презентации
за кандидатстване в чужбина!
Кога: 25.03.2015 г. (сряда)
Къде: Професионална гимназия по икономика - Шумен
Лектори: Консултанти на EDLANTA
За Патронния празник на ПГ по икономика-Шумен - 6 декември 2013 гозина, учениците от Клуб "Историческа лаборатория" изработиха Покани за официалните гости
Учениците от Клуб "Историческа лаборатория", ПГ по икономика-Шумен представиха отлично историята на училището на Патронния празник - 6 декември. Поздравления за Станислава, Джанел, Мария и Йоанна от 9 а клас! Това е синхронизирания текст към презентацията.
The document discusses the globalization of innovation in the pharmaceutical industry. It covers trends showing the rise of innovation capabilities in other countries. Key opportunities for pharmaceutical companies include accessing skilled workforces and scientific capabilities around the world. Drivers enabling global innovation are increasing intellectual property protections, investments in research, and partnerships across countries. Challenges include threats to intellectual property from changes in patent laws and compulsory licensing of drugs. The industry must navigate regulation and litigation while bringing new medicines to patients globally.
Клуб "Историческа лаборатория", ПГ по икономика-Шумен представи историята на училището на Патронния празник - 6 декември 2013 г. Поздравления за Мария, Йоанна, Джанел и Станислава от 9 а клас!
Modeling and simulation has impacted drug development decision-making by allowing evaluation of different study designs, doses, and regimens using computer simulations. For a potential Alzheimer's drug, trial simulations were used to compare different study designs and select a 4x4 Latin square design with 4-week treatment periods. This design was predicted to have the best power to detect drug effects and correctly characterize the dose-response relationship. In another example, population PK/PD modeling of gabapentin clinical trial data supported the drug's efficacy in neuropathic pain at 1800 mg and 2400 mg daily doses.
Безплатни консултации и презентации
за кандидатстване в чужбина!
Кога: 25.03.2015 г. (сряда)
Къде: Професионална гимназия по икономика - Шумен
Лектори: Консултанти на EDLANTA
За Патронния празник на ПГ по икономика-Шумен - 6 декември 2013 гозина, учениците от Клуб "Историческа лаборатория" изработиха Покани за официалните гости
Учениците от Клуб "Историческа лаборатория", ПГ по икономика-Шумен представиха отлично историята на училището на Патронния празник - 6 декември. Поздравления за Станислава, Джанел, Мария и Йоанна от 9 а клас! Това е синхронизирания текст към презентацията.